title: Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction.
abstract: Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug that has been recently approved to provide further risk reduction. The results of two Phase III trials (thrombin receptor antagonists for clinical event reduction and the TRA 2°P-TIMI 50) have showed that vorapaxar, in addition to standard of care therapy, has the potential to provide further risk reduction in patients with prior MI. A search was made on PubMed on articles related to clinical trials and clinical consideration with the use of vorapaxar. This review article summarizes the results of Phase II trials, Phase III trials, subgroup analysis, precautions, and drug interaction with the use of vorapaxar.
authors.affiliation: Division of Pharmacy, School of Medicine, University of Tasmania, Australia.
authors.forename: Obamiro
authors.initials: O
authors.lastname: Kehinde
authors.affiliation: Department of Pharmacology, College of Medicine, University of Lagos, Nigeria.
authors.forename: Rotimi
authors.initials: R
authors.lastname: Kunle
keywords: Antiplatelet; cardiovascular event; myocardial infarction; vorapaxar